Compare · BTMD vs CGC
BTMD vs CGC
Side-by-side comparison of Biote Corp. (BTMD) and Canopy Growth Corporation (CGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTMD and CGC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- CGC is the larger of the two at $2.86B, about 73.4x BTMD ($39.0M).
- CGC has hit the wire 9 times in the past 4 weeks while BTMD has been quiet.
- CGC has more recent analyst coverage (19 ratings vs 4 for BTMD).
- Company
- Biote Corp.
- Canopy Growth Corporation
- Price
- $1.05-4.52%
- $0.72+0.32%
- Market cap
- $39.0M
- $2.86B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 9
- Recent ratings
- 4
- 19
Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Latest BTMD
- Executive Chairman Beer Marc D bought $202,204 worth of shares (131,950 units at $1.53), increasing direct ownership by 122% to 239,744 units (SEC Form 4)
- SEC Form 10-Q filed by Biote Corp.
- Biote Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Biote Reports Second Quarter 2026 Financial Results
- Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call
- Amendment: SEC Form 8-K/A filed by Biote Corp.
- SEC Form 4 filed by Interim CEO Peterson Robert Charles
- SEC Form 4 filed by Director Christensen Bret
- SEC Form 4 filed by Executive Chairman Beer Marc D
- Biote Corp. filed SEC Form 8-K: Leadership Update
Latest CGC
- SEC Form DEFA14A filed by Canopy Growth Corporation
- SEC Form 8-K filed by Canopy Growth Corporation
- Canopy Growth’s Smiths Falls Facility Becomes Canada’s Only EU GMP-Certified Site Combining Softgel Manufacturing With Primary Packaging of Softgels, Oral Liquids and Dried Cannabis Flower
- SEC Form DEFA14A filed by Canopy Growth Corporation
- Director Yanofsky Theresa sold $13,828 worth of shares (14,920 units at $0.93), decreasing direct ownership by 10% to 131,495 units (SEC Form 4) to satisfy withholding obligation
- Director Lazzarato David Angelo sold $20,742 worth of shares (22,380 units at $0.93), decreasing direct ownership by 11% to 189,479 units (SEC Form 4) to satisfy tax liability
- Director Bayern Joseph sold $2,869 worth of shares (3,096 units at $0.93), decreasing direct ownership by 2% to 142,031 units (SEC Form 4) to cover withholding tax
- Director Atkins M Shan sold $2,869 worth of shares (3,096 units at $0.93), decreasing direct ownership by 2% to 143,421 units (SEC Form 4) (for withholding tax)
- Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany
- SEC Form DEFA14A filed by Canopy Growth Corporation